CYTOO and Pfizer Inc. have entered a research collaboration to modify CYTOO’s existing MyoScreen platform to enable its potential use as a Duchenne muscular dystrophy (DMD) target discovery platform. Financial terms were not disclosed. DMD is a rare and life-threatening genetic disorder caused by mutations in the dystrophin gene that results in progressive muscle degeneration and weakness. CYTOO has developed a muscle-on-a-plate platform using patients’ primary cells, called MyoScreen. MyoScr...